An Imaging and Histopathologic Study to Predict Response to Sunitinib Therapy in Patients With Metastatic Renal Cell Carcinoma.

Trial Profile

An Imaging and Histopathologic Study to Predict Response to Sunitinib Therapy in Patients With Metastatic Renal Cell Carcinoma.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 14 Dec 2015 Status changed from completed to active, no longer recruiting, as reported by ClinicalTrials.gov (NCT01026337).
    • 14 Dec 2015 Status changed from completed to active, no longer recruiting, as reported by ClinicalTrials.gov (NCT01026337).
    • 24 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov (NCT01026337)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top